Society Logo
ME/CFS Australia Ltd
Please click here to donate ME/CFS Australia (SA) Inc
 
 
Facebook
 
ME/CFS AUSTRALIA (SA) INC

Registered Charity 698

Email:
sacfs@sacfs.asn.au

Mailing address:
PO Box 28,
Hindmarsh,
South Australia 5007

Office:
Suite 506,
North Terrace House,
19 North Terrace,
Hackney, SA, 5069


Phone:
1300 128 339

Office Hours:
Wednesdays, 11am-3pm

ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.

Disclaimer

ME/CFS Australia (SA) Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
PDF Application Form (PDF, 277KB)
Why become a member?

UK Fibromyalgia sufferers petition the National Health Service to integrate and pay for ActiPatch® therapy

Saturday 29 November 2014

 

From the BioElectronics Corporation:

 

ActiPatch®
ActiPatch®
 

UK Fibromyalgia Sufferers Petition the National Health Service to Integrate and Pay for BioElectronics’ ActiPatch® Therapy

FREDERICK, MD, USA, November 26, 2014 — BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced consumer and healthcare medical devices announced today that Pifflers United Chronic and Invisible Illnesses Support Community, www.facebook.com/PifflersUnited, is petitioning the United Kingdom’s NHSNational Institute for Health & Care Excellence (NICE) for new guidelines for effective Fibromyalgia pain management.

Fibromyalgia (FM) is a chronic condition of widespread pain and profound fatigue. The pain tends to be felt as diffuse aching or burning, often described as head to toe. Fibromyalgia patients receive ad hoc treatment and NICE Guidelines for the treatment of Fibromyalgia are needed to ensure sufferers are treated appropriately and consistently.

The group members used ActiPatch® Therapy and were surveyed. Upon completion, the survey showed an average pain reduction of 33% with 79% of them reporting a pain decrease. When analyzed excluding those with no or very little pain improvement, the therapeutic rate was 69% with a 47% reduction in pain.

The Pifflers United petition calls on the UK Government to roll out a cohesive plan for the treatment and management of Fibromyalgia, including the following:

1) Produce NICE Guidelines for the treatment of Fibromyalgia

2) Arrange for Clinical Trials of the ActiPatch device, following on from the 7-day trial results conducted by Fibromyalgia sufferers in the online support community.

3) Following on from successful clinical trials of ActiPatch, to arrange for the ActiPatch device to be available on prepay prescription for the treatment and management of Fibromyalgia pain.

To view the e-petition and study results, please visit www.facebook.com/PifflersUnited.

About BioElectronics Corporation
BioElectronics Corporation is a leader in biophysics and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy; and HealFast® Therapy for dogs, cats and horses. For more information, please visit www.bielcorp.com.

BioElectronics Contact:
Paul Knopick
940.262.3584
pknopick@eandecommunications.com

 

The above originally appeared here.

 


Arrow right

More Fibromyalgia News

 


Arrow right

More Multimedia

 


 

blog comments powered by Disqus

Previous Previous Page